蔚蓝生物
(603739)
| 流通市值：34.34亿 | | | 总市值：34.34亿 |
| 流通股本：2.53亿 | | | 总股本：2.53亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 652,193,328.83 | 310,197,929.93 | 1,320,761,061.74 | 945,618,593.2 |
| 营业收入 | 652,193,328.83 | 310,197,929.93 | 1,320,761,061.74 | 945,618,593.2 |
| 二、营业总成本 | 611,538,303.12 | 293,945,014.79 | 1,222,005,770.44 | 881,905,556.31 |
| 营业成本 | 358,237,347.47 | 172,593,365.91 | 725,808,660.93 | 527,857,116 |
| 税金及附加 | 6,765,761.08 | 3,400,130.96 | 13,221,888.06 | 9,913,292.49 |
| 销售费用 | 105,168,275.54 | 49,401,628.1 | 197,380,400.84 | 139,421,562.36 |
| 管理费用 | 68,690,483.58 | 35,652,170.83 | 146,598,499.14 | 107,265,270.05 |
| 研发费用 | 63,882,939.04 | 28,494,054.14 | 118,222,310.22 | 81,303,889.41 |
| 财务费用 | 8,793,496.41 | 4,403,664.85 | 20,774,011.25 | 16,144,425.99 |
| 其中:利息费用 | 11,699,465.59 | 4,282,179.3 | 21,878,828.93 | 16,374,941.9 |
| 其中:利息收入 | -422,077.03 | -147,205.94 | 1,525,111.73 | -1,193,650.95 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,166,982.33 | 495 | 8,317,637.54 | 470,143.27 |
| 加:投资收益 | -126,522.53 | 1,661,922.5 | -1,239,485.35 | 3,965,899.11 |
| 资产处置收益 | 393,279.13 | - | 602,390.96 | 566,953.65 |
| 资产减值损失(新) | 860,799.97 | 167,960.88 | -2,684,134.98 | 519,852.13 |
| 信用减值损失(新) | -2,960,723.86 | 2,258,789.16 | -6,467,361.25 | -3,865,898.14 |
| 其他收益 | 10,959,304.49 | 4,247,123.77 | 26,739,205.79 | 17,042,774.3 |
| 四、营业利润 | 53,948,145.24 | 24,589,206.45 | 124,023,544.01 | 82,412,761.21 |
| 加:营业外收入 | 325,758.6 | 218,331.98 | 81,583.65 | 72,607.52 |
| 减:营业外支出 | 1,198,953.67 | 434,093.59 | 661,210.77 | 51,783.28 |
| 五、利润总额 | 53,074,950.17 | 24,373,444.84 | 123,443,916.89 | 82,433,585.45 |
| 减:所得税费用 | 13,270,532.7 | 7,787,082.66 | 31,271,642.41 | 21,365,718.55 |
| 六、净利润 | 39,804,417.47 | 16,586,362.18 | 92,172,274.48 | 61,067,866.9 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 39,804,417.47 | 16,586,362.18 | 92,172,274.48 | 61,067,866.9 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 26,716,293.11 | 9,576,827.68 | 62,637,482.98 | 40,847,212.04 |
| 少数股东损益 | 13,088,124.36 | 7,009,534.5 | 29,534,791.5 | 20,220,654.86 |
| 扣除非经常损益后的净利润 | 16,002,005.78 | 5,259,509.61 | 25,154,344.46 | 23,276,488.34 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.11 | 0.04 | 0.25 | 0.16 |
| (二)稀释每股收益 | 0.11 | 0.04 | 0.25 | 0.16 |
| 八、其他综合收益 | -166,749.78 | - | 1,256,980.5 | -58,423.12 |
| 归属于母公司股东的其他综合收益 | -134,355.02 | - | 1,271,958.72 | -41,480.72 |
| 九、综合收益总额 | 39,637,667.69 | 16,586,362.18 | 93,429,254.98 | 61,009,443.78 |
| 归属于母公司股东的综合收益总额 | 26,581,938.09 | 9,576,827.68 | 63,909,441.7 | 40,805,731.32 |
| 归属于少数股东的综合收益总额 | 13,055,729.6 | 7,009,534.5 | 29,519,813.28 | 20,203,712.46 |
| 公告日期 | 2025-08-28 | 2025-04-26 | 2025-04-26 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |